Multimodality of BP modulating agents in acute stroke
| Beneficial effects | Detrimental effects | ||||||
|---|---|---|---|---|---|---|---|
| Agent | Anti-inflammation | Smooth muscle cell antiproliferation | Cerebral vasodilatation | Neuroprotection | Antiplatelet* | Negative inotrope | Stress hormone attenuation |
| α2-adrenoreceptor agonist49–51 | + | − | |||||
| α and β-Blocker49 | − | − | |||||
| ACEi52 53 | + | + | + | + | − | ||
| ARA54 55 | + | + | + | − | |||
| β-blocker56 57 | − | − | − | ||||
| CCA57 | − | − | |||||
| Magnesium58–61 | + | + | − | ||||
| NO donor62–65 | + | + | + | + | − (SNP) | ||
Broad categories of other potential effects of BP modulating agents, with over-arching beneficial and detrimental groups. ‘+’=Beneficial effects, ‘−’=Detrimental effects, ‘*’=In the context of ICH, antiplatelet properties are potentially detrimental.
ACEi, ACE inhibitors; ARA, angiotensin receptor antagonists; CCA, calcium channel antagonists; NO, nitric oxide; SNP, sodium nitroprusside.